GENinCode Plc (GENI.L)
| Previous Close | 8.25 |
| Open | 8.50 |
| Bid | 8.00 x N/A |
| Ask | 8.50 x N/A |
| Day's Range | 8.31 - 8.50 |
| 52 Week Range | 3.34 - 14.00 |
| Volume | |
| Avg. Volume | 399,963 |
| Market Cap | 14.776M |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.06 |
| Earnings Date | Jun 04, 2024 - Jun 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.00 |
ACCESSWIRECARDIO inCode-Score (CIC-Score) Presentation at the European Society of Cardiology
Preventive Cardiology Congress Athens 2024 OXFORD, ENGLAND / ACCESSWIRE / May 1, 2024 /GENinCode Plc, the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, gave details of a presentation by Kaiser Permanente ...
ACCESSWIRECARDIO inCode-Score Clinical Publication on Polygenic Risk of Coronary Heart Disease
US Study Publication in the American Journal of Preventive Cardiology OXFORD, UK / ACCESSWIRE / April 5, 2024 / GENinCode Plc ( www.genincode.com ) the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces ...
ACCESSWIRECARDIO inCode Study Results Presented at ESC Annual Meeting
GENinCode Plc (AIM - GENI), the polygenics company focused on the prevention of cardiovascular disease, announced the presentation by Kaiser Permanente on the 'Utility of the CARDIO inCode-Score CHD polygenic risk score for incident coronary heart disease interplay with lifestyle in a multi-ethnic cohort of more than 60,000 individuals.' The presentation was made at the Annual Meeting of the European Society of Cardiologists ("ESC") Congress from
